IL140324A0 - Inhibition of transcription factor nf-kb - Google Patents

Inhibition of transcription factor nf-kb

Info

Publication number: IL140324A0
Authority: IL; Israel
Prior art keywords: inhibition; transcription factor; transcription; factor
Prior art date: 1998-06-19

Application number

IL14032499A

Other languages

English (en)

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-19

Filing date

1999-06-18

Publication date

2002-02-10

1999-06-18 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2002-02-10 Publication of IL140324A0 publication Critical patent/IL140324A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Virology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Toxicology (AREA)
Transplantation (AREA)

IL14032499A 1998-06-19 1999-06-18 Inhibition of transcription factor nf-kb IL140324A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9001698P	1998-06-19	1998-06-19
PCT/US1999/013897 WO1999065495A1 (en)	1998-06-19	1999-06-18	INHIBITORS OF TRANSCRIPTION FACTOR NF-λB

Publications (1)

Publication Number	Publication Date
IL140324A0 true IL140324A0 (en)	2002-02-10

Family

ID=22220761

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14032499A IL140324A0 (en)	1998-06-19	1999-06-18	Inhibition of transcription factor nf-kb

Country Status (17)

Country	Link
EP (1)	EP1085872A4 (xx)
JP (1)	JP2002518333A (xx)
KR (1)	KR20010052990A (xx)
CN (1)	CN1306428A (xx)
AR (1)	AR019871A1 (xx)
AU (1)	AU4699699A (xx)
BR (1)	BR9911151A (xx)
CA (1)	CA2335293A1 (xx)
CO (1)	CO5080752A1 (xx)
CZ (1)	CZ20004760A3 (xx)
HU (1)	HUP0102492A2 (xx)
IL (1)	IL140324A0 (xx)
NO (1)	NO20006452L (xx)
PL (1)	PL345577A1 (xx)
TR (1)	TR200003779T2 (xx)
WO (1)	WO1999065495A1 (xx)
ZA (1)	ZA200007448B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE951551T1 (de)	1996-12-23	2000-09-14	Immunex Corp., Seattle	Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
ATE412746T1 (de)	1998-05-14	2008-11-15	Immunex Corp	Verfahren zur hemmung der wirkung der osteoklasten
WO2001052892A2 (en) *	2000-01-24	2001-07-26	Genzyme Corporation	Jak/stat pathway inhibitors and the uses thereof
US20060148732A1 (en) *	2000-11-17	2006-07-06	Gutterman Jordan U	Inhibition of NF-kappaB by triterpene compositions
EP1409016B9 (en)	2001-06-26	2020-10-28	Amgen Fremont Inc.	Antibodies to opgl
US7425580B2 (en)	2004-05-19	2008-09-16	Wyeth	(Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
WO2007097981A2 (en)	2006-02-16	2007-08-30	Millennium Pharmaceuticals, Inc.	Alpha carbolines and uses thereof
RU2504544C2 (ru)	2008-10-02	2014-01-20	Асахи Касеи Фарма Корпорейшн	8-замещенные производные изохинолина и их применение
WO2010108058A2 (en)	2009-03-20	2010-09-23	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Small molecule inhibitors of dusp6 and uses therefor
WO2011014825A2 (en) *	2009-07-31	2011-02-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antiangiogenic small molecules and methods of use
US10160705B2 (en)	2011-02-10	2018-12-25	University of Pittsburgh—of the Commonwealth System of Higher Education	Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2014071000A1 (en)	2012-10-31	2014-05-08	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

1998
- 1998-06-18 HU HU0102492A patent/HUP0102492A2/hu unknown
1999
- 1999-06-17 CO CO99037918A patent/CO5080752A1/es unknown
- 1999-06-18 AR ARP990102952A patent/AR019871A1/es unknown
- 1999-06-18 EP EP99930459A patent/EP1085872A4/en not_active Withdrawn
- 1999-06-18 BR BR9911151-9A patent/BR9911151A/pt not_active Application Discontinuation
- 1999-06-18 CN CN99807572A patent/CN1306428A/zh active Pending
- 1999-06-18 JP JP2000554375A patent/JP2002518333A/ja not_active Withdrawn
- 1999-06-18 IL IL14032499A patent/IL140324A0/xx unknown
- 1999-06-18 WO PCT/US1999/013897 patent/WO1999065495A1/en not_active Application Discontinuation
- 1999-06-18 PL PL99345577A patent/PL345577A1/xx not_active Application Discontinuation
- 1999-06-18 AU AU46996/99A patent/AU4699699A/en not_active Abandoned
- 1999-06-18 CA CA002335293A patent/CA2335293A1/en not_active Abandoned
- 1999-06-18 TR TR2000/03779T patent/TR200003779T2/xx unknown
- 1999-06-18 KR KR1020007014385A patent/KR20010052990A/ko not_active Withdrawn
- 1999-06-18 CZ CZ20004760A patent/CZ20004760A3/cs unknown
2000
- 2000-12-13 ZA ZA200007448A patent/ZA200007448B/en unknown
- 2000-12-18 NO NO20006452A patent/NO20006452L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2335293A1 (en)	1999-12-23
CO5080752A1 (es)	2001-09-25
AR019871A1 (es)	2002-03-20
CZ20004760A3 (cs)	2001-08-15
AU4699699A (en)	2000-01-05
EP1085872A1 (en)	2001-03-28
HUP0102492A2 (hu)	2001-11-28
WO1999065495A1 (en)	1999-12-23
BR9911151A (pt)	2001-03-06
KR20010052990A (ko)	2001-06-25
CN1306428A (zh)	2001-08-01
JP2002518333A (ja)	2002-06-25
NO20006452L (no)	2001-02-16
EP1085872A4 (en)	2003-04-16
NO20006452D0 (no)	2000-12-18
TR200003779T2 (tr)	2001-06-21
PL345577A1 (en)	2001-12-17
ZA200007448B (en)	2001-12-12

Publication	Publication Date	Title
IL140328A0 (en)	2002-02-10	Inhibitors of transcription factor nf-kb
AU2002213002A1 (en)	2002-04-15	Antisense inhibition of caspase 6 expression
EP1143953A3 (en)	2002-02-06	Method of inhibiting angiogenesis
AU6229699A (en)	2000-05-15	Beta-amyloid formation inhibitors
IL143535A0 (en)	2002-04-21	Inhibitors of multidrug transporters
IL140324A0 (en)	2002-02-10	Inhibition of transcription factor nf-kb
TW470199U (en)	2001-12-21	Structure of maintaining portion for cymbals
AU6274299A (en)	2000-04-17	Inhibition of pak activation of raf-1
AU4369000A (en)	2000-11-10	Inhibition of complement action
WO2000001393A8 (en)	2007-08-30	OLIGONUCLEOTIDE INHIBITORS OF bcl-xL
AU5673099A (en)	2000-03-06	Inhibitors of amyloid formation
AU4440199A (en)	2000-02-14	Methods and compositions for inhibition of angiogenesis
IL134210A0 (en)	2001-04-30	Use of transcription factor brn-3a
AU5200699A (en)	2000-02-01	Inhibition of lipoprotein formation
AU5126298A (en)	1998-06-03	Inhibition of crib-biting
IL141537A0 (en)	2002-03-10	Promotion or inhibition of angiogenesis and cardiovascularization
AU6578298A (en)	1998-10-20	Antisense inhibition of angiogenin expression
AU6218599A (en)	2000-05-01	Inhibition of titanium corrosion
HK1035667A (en)	2001-12-07	INHIBITORS OF TRANSCRIPTION FACTOR NF-κB
HK1035668A (en)	2001-12-07	INHIBITORS OF TRANSCRIPTION FACTOR NF-κB
AUPP751198A0 (en)	1999-01-07	Purification of A1-proteinase inhibitor
AU2722600A (en)	2000-07-24	Inhibition of cd4-ccr5 interaction
GB9904070D0 (en)	1999-04-14	Inhibition of scale
TW400927U (en)	2000-08-01	Improvement of screw
GB9922779D0 (en)	1999-11-24	Inhibition of corrosion